Press Resease

Antibiotics Market -By Drug Class (Cephalosporins, Penicillin, and Fluoroquinolones), By Action Mechanism (DNA, Protein, Cell Wall Synthesis Inhibitors, and RNA) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 31-Jul-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-4064 Status : Published

Global Antibiotics market, which accrued revenue worth 47 (USD Billion) in 2019, is set to record the CAGR of nearly 4.2% over the period from 2020 to 2026.

Description

The global Antibiotics market, which accrued revenue worth 47 (USD Billion) in 2019, is set to record the CAGR of nearly 4.2% over the period from 2020 to 2026. The report offers assessment and analysis of the Antibiotics market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion).

Introduction

In the first half of twentieth century, illness due to contagious agents caused most of the deaths in North America as well as across the globe. However, with the discovery of penicillin in 1928 and medical utilization of sulphonamides in 1930, antibiotic treatment gained prominence. With extensive usage of penicillin in 1940s and introduction of new kinds of antibiotics within the next two decades, the market begin to gain traction. From 1935 till 2003 many new types of antibiotics were introduced and this include sulphonamides, penicillin, aminoglycosides, cephalosporin, chloramphenicol, tetracycline, macrolides, glycopeptides, rapamycin, nitroimidazoles, quinolones, oxazolidinones, and lipopeptides.

Moreover, launching of new antibiotics was considered to eradicate contagious diseases completely. However, with resurgence of new diseases and threat of bioterrorism & genetically engineered pathogens like Bacillus anthracis has compelled the researchers to develop new antibiotics. Hence, with occurrence of new type of antimicrobial resistance microbes, it has become necessary to create new antibiotics to combat these microbes. This has also resulted in growing significance of antibiotics drug treatment in the current years. With spread of COVID-19 across the globe, the antibiotics industry is likely to flourish over the coming decades.

According to Lancet, WHO classified antibiotic intake into three categories namely, Watch, Reserve, and Access for seventy-six nations during 2000 to 2015.

Market Growth Dynamics

Surge in the incidences of chronic disorders has resulted in the demand for development of new medicines and this is likely to translate into market expansion over the estimated timespan. Growing efforts as well as investments made by the key firms in research & development for producing new drugs will prompt the expansion of antibiotics industry over the forecast timespan.

Furthermore, favorable government laws like generating antibiotics incentives now act is projected to expedite the development of antibiotic treatments against pathogens and this will steer the market growth. Need for curbing chronic ailments including Zika virus, pneumonia, COVID-19, cancer, tuberculosis, Ebola virus, and malaria will provide impetus to the growth of the industry over the estimated timespan. Product innovation as well as addition of new products to existing product line as well as private-public strategic alliances & joint ventures will prop up the market size in the foreseeable future.

Asia Pacific Market To Record Tremendous Growth Over 2020-2026

The growth of the market in Asia Pacific zone over 2020-2026 is owing to high incidences of contagious ailments, regulations promoting use of generic medicines, and favorable government laws. Additionally, inflating population and unhygienic conditions will further contribute towards the regional industry growth.

Key players profiled in the report include Novartis AG, Bayer AG, Janssen Pharmaceuticals, Astellas Pharma, Inc., Pfizer, Inc., GlaxoSmithKline plc, Bristol Myers Squibb Company, Abbott Laboratories, Sanofi S.A., and Eli Lilly and Company.

The global antibiotics market is segmented as follows:

By Action Mechanism

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors

By Drug Class

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides
  • Other

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Antibiotics Market , 2016–2026(USD Billion)
    • 2.2. Antibiotics Market : Snapshot
  • Chapter 3. Global Antibiotics Market – Industry Analysis
    • 3.1. Antibiotics Market : Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Growing efforts as well as investments made by the key firms in research & development for producing new drugs will prompt the expansion of antibiotics industry over the forecast timespan.
      • 3.2.2. Favorable government laws like generating antibiotics incentives now act is projected to expedite the development of antibiotic treatments against pathogens and this will steer the market growth.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Drug Class
      • 3.4.2. Market attractiveness analysis By Action Mechanism
  • Chapter 4. Global Antibiotics Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Antibiotics Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Antibiotics Market–Drug Class Analysis
    • 5.1. Global Antibiotics Market overview: By Drug Class
      • 5.1.1. Global Antibiotics Market share, By Drug Class,2019 and 2026
    • 5.2. Cephalosporins
      • 5.2.1. Global Antibiotics Market by Cephalosporins , 2016–2026(USD Billion)
    • 5.3. Penicillin
      • 5.3.1. Global Antibiotics Market by Penicillin , 2016–2026(USD Billion)
    • 5.4. Fluoroquinulones
      • 5.4.1. Global Antibiotics Market by Fluoroquinulones , 2016–2026(USD Billion)
  • Chapter 6. Global Antibiotics Market–Action Mechanism Analysis
    • 6.1. Global Antibiotics Market overview: By Action Mechanism
      • 6.1.1. Global Antibiotics Market share, By Action Mechanism , 2019 and 2026
    • 6.2. DNA
      • 6.2.1. Global Antibiotics Market By DNA , 2016–2026(USD Billion)
    • 6.3. Protein
      • 6.3.1. Global Antibiotics Market By Protein, 2016–2026(USD Billion)
    • 6.4. Cell Wall Synthesis Inhibitors
      • 6.4.1. Global Antibiotics Market By Cell Wall Synthesis Inhibitors, 2016–2026(USD Billion)
    • 6.5. RNA
      • 6.5.1. Global Antibiotics Market By RNA, 2016–2026(USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. Janssen Pharmaceuticals
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Pfizer, Inc.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. GlaxoSmithKline plc
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Abbott Laboratories
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Novartis AG
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Sanofi S.A.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Bristul Myers Squibb Company
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Bayer AG
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Astellas Pharma, Inc.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Eli Lilly and Company
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development

Methodology


Frequently Asked Questions

Surge in the incidences of chronic disorders has resulted in the demand for development of new medicines and this is likely to translate into market expansion over the estimated timespan.

The CAGR of the industry is expected to be nearly 4.2% during the forecast timeline.

Asia Pacific will contribute remarkably towards the global market share over the estimated timeline.

The key market players include Janssen Pharmaceuticals; Pfizer, Inc.; GlaxoSmithKline plc; Abbott Laboratories; Novartis AG; Sanofi S.A.; Bristol Myers Squibb Company; Bayer AG; Astellas Pharma, Inc; and Eli Lilly and Company.
}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com